645 results match your criteria u373 tumors

Silencing ZEB2 Induces Apoptosis and Reduces Viability in Glioblastoma Cell Lines.

Molecules 2021 Feb 9;26(4). Epub 2021 Feb 9.

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 51656-65811, Iran.

Background: Glioma is an aggressive type of brain tumor that originated from neuroglia cells, accounts for about 80% of all malignant brain tumors. Glioma aggressiveness has been associated with extreme cell proliferation, invasion of malignant cells, and resistance to chemotherapies. Due to resistance to common therapies, glioma affected patients' survival has not been remarkably improved. Read More

View Article and Full-Text PDF
February 2021

Harmine inhibits the proliferation and migration of glioblastoma cells via the FAK/AKT pathway.

Life Sci 2021 Apr 26;270:119112. Epub 2021 Jan 26.

Institute of Translational Medicine, Nanchang University, 1299 Xuefu Avenue, Nanchang, Jiangxi 330001, PR China. Electronic address:

Aims: Glioblastoma is one of the most invasive tumors of the central nervous system, and has a high degree of malignancy and poor prognosis. Harmine, an active ingredient extracted from perennial herbs, has been reported to have obvious antitumor effects on various tumors. However, the effects of harmine on glioblastoma growth remain unknown. Read More

View Article and Full-Text PDF

The Role of ZEB2 Expression in Pediatric and Adult Glioblastomas.

Anticancer Res 2021 Jan;41(1):175-185

Department of Pathology, Seoul National University Hospital, College of Medicine, Seoul, Republic of Korea

Background/aim: Both pediatric glioblastoma (pGB) and adult glioblastoma (aGB) are clinically devastating, and are known to have different molecular pathogenesis. Here, we focused on the role of ZEB2 in pGB and aGB.

Materials And Methods: Following transfection with ZEB2 siRNA into pGB cells (KNS42) and aGB cells (U87 and U373), cell proliferation, migration and invasion, and cell cycle progression were evaluated. Read More

View Article and Full-Text PDF
January 2021

RAD51-Mediated DNA Homologous Recombination Is Independent of Mutational Status.

Cancers (Basel) 2020 Oct 29;12(11). Epub 2020 Oct 29.

Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB R3E 0T6, Canada.

PTEN mutation occurs in a variety of aggressive cancers and is associated with poor patient outcomes. Recent studies have linked mutational loss of to reduced RAD51 expression and function, a key factor involved in the homologous recombination (HR) pathway. However, these studies remain controversial, as they fail to establish a definitive causal link to RAD51 expression that is PTEN-dependent, while other studies have not been able to recapitulate the relationship between the PTEN expression and the RAD51/HR function. Read More

View Article and Full-Text PDF
October 2020

DRAQ7 as an Alternative to MTT Assay for Measuring Viability of Glioma Cells Treated With Polyphenols.

Anticancer Res 2020 Oct;40(10):5427-5436

Flow Cytometry Facility, The Francis Crick Institute, London, U.K.

Background/aim: The tetrazolium-based MTT cytotoxicity assay is well established for screening putative anti-cancer agents. However, it has limitations including lack of reproducibility with glioma cells treated with polyphenols. The aim of this study was to evaluate whether a flow cytometric assay with the anthraquinone, DRAQ7, was a better alternative than the colorimetric MTT assay for measuring cell viability. Read More

View Article and Full-Text PDF
October 2020

Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.

Neurotherapeutics 2020 10;17(4):2015-2027

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.

Glioblastomas (GBMs) are the most aggressive tumor type of the central nervous system, mainly due to their high invasiveness and innate resistance to radiotherapy and chemotherapy, with temozolomide (TMZ) being the current standard therapy. Recently, brachyury was described as a novel tumor suppressor gene in gliomas, and its loss was associated with increased gliomagenesis. Here, we aimed to explore the role of brachyury as a suppressor of glioma invasion, stem cell features, and resistance to TMZ. Read More

View Article and Full-Text PDF
October 2020

MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line.

Asian Pac J Cancer Prev 2020 Jun 1;21(6):1747-1753. Epub 2020 Jun 1.

Department of Anatomy, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.

Background: Deregulation of the EGFR signaling pathway activity has been shown to can be effective in resistance to EGFR-TKIs, such as Tarceva (erlotinib), in glioblastoma cells. In addition, reports have shown that the reduction of miRNA-7 expression levels is associated with an increase in the expression of EGFR. Here, we evaluated the effect of miRNA-7 on EGFR expression and sensitivity of the U373-MG glioblastoma to erlotinib. Read More

View Article and Full-Text PDF

PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR.

Biomolecules 2020 04 10;10(4). Epub 2020 Apr 10.

Department of Experimental Medicine, "Sapienza" University of Rome, Italy, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, 00161 Rome Italy.

Phenylbutyrate (PBA) is a derivative of Butyric Acid (BA), which has the characteristics of being a histone deacetylase (HDAC) inhibitor and acting as a chemical chaperone. It has the potential to counteract a variety of different diseases, from neurodegeneration to cancer. In this study, we investigated the cytotoxic effect of PBA against glioblastoma cells carrying wt or mutant (mut) p53 and found that it exerted a higher cytotoxic effect against the latter in comparison with the former. Read More

View Article and Full-Text PDF

MiRNA-7 enhances erlotinib sensitivity of glioblastoma cells by blocking the IRS-1 and IRS-2 expression.

J Pharm Pharmacol 2020 Apr 5;72(4):531-538. Epub 2020 Feb 5.

Department of Molecular Medicine and Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.

Objectives: Down-regulation of miRNA-7 is correlated with over-expression of IRS-1 and IRS-2 proteins, the upstream regulators of IGF-1R/Akt pathway, in glioblastoma cells. In this study, the effect of miRNA-7 on expression of IRS-1 and IRS-2 and sensitivity of the U373-MG glioblastoma cells to erlotinib was explored.

Methods: After miRNA-7 transfection, the expression of IRS-1 and IRS-2 mRNAs was measured by RT-qPCR. Read More

View Article and Full-Text PDF

EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.

Pathol Oncol Res 2020 Oct 27;26(4):2135-2141. Epub 2020 Jan 27.

epartment of Neurosurgery, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, 215300, People's Republic of China.

Glioblastoma multiforme (GBM) is the most malignant form of the brain tumors. EGFR variant III (EGFRvIII) is expressed in about 30% of GBM specimens, but not expressed in normal brain tissues. Therefore, EGFRvIII protein offers an ideal CAR-T therapeutic target for EGFRvIII-positive GBM patients. Read More

View Article and Full-Text PDF
October 2020

Crocetin Extracted from Saffron Shows Antitumor Effects in Models of Human Glioblastoma.

Int J Mol Sci 2020 Jan 9;21(2). Epub 2020 Jan 9.

Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Over recent years, many authors discussed the effects of different natural compounds on glioblastoma (GBM). Due to its capacity to impair survival and progression of different cancer types, saffron extract (SE), named crocetin (CCT), is particularly noteworthy. In this work, we elucidated the antitumor properties of crocetin in glioma in vivo and in vitro models for the first time. Read More

View Article and Full-Text PDF
January 2020

MAGI1 Inhibits the Proliferation, Migration and Invasion of Glioma Cells.

Onco Targets Ther 2019 19;12:11281-11290. Epub 2019 Dec 19.

Department of Anatomy, College of Basic Medical Sciences, China Medical University, Shenyang, People's Republic of China.

Background: Membrane-associated guanylate kinase inverted repeat member 1 (MAGI1) acts as a tumor suppressor in a variety of tumors; however, its expression and biological function in glioma are still unknown.

Methods: MAGI1 expression in glioma was examined by immunohistochemistry. In addition, overexpression of MAGI1 in U87 and U373 cells, colony formation and MTT assays were used to evaluate cell proliferation, Transwell assays to determine cell migration and invasion, and a xenograft model established using U87 cells to evaluate the effect of MAGI1 overexpression in vivo. Read More

View Article and Full-Text PDF
December 2019

Kisspeptin Promotes Glioblastoma Cell Invasiveness the Gq-PLC-PKC Pathway.

Anticancer Res 2020 Jan;40(1):213-220

Department of Biotechnology, Korea National University of Transportation, Chungbuk, Republic of Korea

Background/aim: Kisspeptin produced from the KISS1 gene is secreted from the living cells, binds to endogenous receptor KISS1R (also called G protein-coupled receptor 54, GPR54), and has various functions in normal physiological conditions. Although an anti-metastatic role of kisspeptin in cancer is well known in several cancer types, its role in brain tumors is not yet understood. Herein, we investigated a the role of kisspeptin in glioblastoma cells. Read More

View Article and Full-Text PDF
January 2020

Alpinumisoflavone suppresses human Glioblastoma cell growth and induces cell cycle arrest through activating peroxisome proliferator-activated receptor-γ.

Anat Rec (Hoboken) 2020 11 8;303(11):2801-2810. Epub 2020 Jan 8.

Cancer Center, Jiangyin People's Hospital, Jiangyin, China.

As a common subtype of malignant gliomas, glioblastoma multiforme (GBM) is associated with poor prognosis. This study is aimed to examine the anticancer activities of alpinumisoflavone (AIF) and its underlying mechanisms. Our results demonstrated that AIF inhibited the proliferation of GBM cells (U373 and T98G) in a time and dose-dependent manner. Read More

View Article and Full-Text PDF
November 2020

LncRNA H19 promotes glioma angiogenesis through miR-138/HIF-1α/VEGF axis.

Neoplasma 2020 Jan 26;67(1):111-118. Epub 2019 Nov 26.

Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

Glioma is one of the most common and aggressive malignant primary brain tumors with high recurrence rate and mortality rate and heavily depends on the angiogenesis. LncRNA H19 has many diverse biological functions, including the regulation of cell proliferation, differentiation and metabolism. Here, we aimed to investigate the molecular mechanism of lncRNA H19 affecting angiogenesis in glioma, which could help to uncover potential target for glioma therapy. Read More

View Article and Full-Text PDF
January 2020

α-Hispanolol Induces Apoptosis and Suppresses Migration and Invasion of Glioblastoma Cells Likely Downregulation of MMP-2/9 Expression and p38MAPK Attenuation.

Front Pharmacol 2019 3;10:935. Epub 2019 Sep 3.

Unidad de Terapias Farmacológicas, Área de Genética Humana, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III, Madrid, Spain.

α-Hispanolol (α-H) is a labdane diterpenoid that has been shown to induce apoptosis in several human cancer cells. However, the effect of α-H in human glioblastoma cells has not been described. In the present work, we have investigated the effects of α-H on apoptosis, migration, and invasion of human glioblastoma cells with the aim of identifying the molecular targets underlying its mechanism of action. Read More

View Article and Full-Text PDF
September 2019

Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma.

Acta Neurochir (Wien) 2019 08 11;161(8):1733-1741. Epub 2019 Jun 11.

Neurosurgical Department, Son Espases University Hospital, 79, carretera de Valldemossa, 07120, Majorca, Spain.

Background: 5-Aminolevulinic acid (5-ALA) has become an important assistant in glioblastoma (GB) surgery. Unfortunately, its price affects its widespread use.

Objective: The aim of this study was to compare commercial 5-ALA with the pharmacy-compounded solution. Read More

View Article and Full-Text PDF

Bufothionine Promotes Apoptosis via Triggering ER Stress and Synergizes with Temozolomide in Glioblastoma Multiforme Cells.

Anat Rec (Hoboken) 2019 11 14;302(11):1950-1957. Epub 2019 Aug 14.

The First People's Hospital of Jining, Jining, China.

Glioblastoma multiforme (GBM) is the most common type of malignant glioma. Bufothionine is one of the major active ingredients of Cinobufacini. Although the antitumor activities of bufothionine have been reported, the underlying mechanism remains unclear. Read More

View Article and Full-Text PDF
November 2019

LITAF Enhances Radiosensitivity of Human Glioma Cells via the FoxO1 Pathway.

Cell Mol Neurobiol 2019 Aug 16;39(6):871-882. Epub 2019 May 16.

Cancer Research Institute of PLA, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.

Lipopolysaccharide-induced tumor necrosis factor alpha factor (LITAF), also called p53-induced gene 7 (PIG7), was identified as a transcription factor that activates transcription of proinflammatory cytokines in macrophages in response to lipopolysaccharide (LPS). Previous studies have identified LITAF as a potential tumor suppressor in several neoplasms, including prostate cancer, B-NHL, acute myeloid leukemia, and pancreatic cancer. However, the expression and function of LITAF in human glioma remain unexplained. Read More

View Article and Full-Text PDF

Effectiveness of a Fractionated Therapy Scheme in Tumor Treating Fields Therapy.

Technol Cancer Res Treat 2019 01;18:1533033819845008

1 Department of Bio-convergence Engineering, Korea University, Seoul, Korea.

This study aimed to evaluate the biological effectiveness of cancer therapy with tumor treating fields using a fractionated treatment scheme that was originally designed for radiotherapy. Discontinuous fractional tumor treating fields of an intensity of 0.9 to 1. Read More

View Article and Full-Text PDF
January 2019

Inhibition of Proliferation by Knockdown of Transmembrane (TMEM) 168 in Glioblastoma Cells via Suppression of Wnt/β-Catenin Pathway.

Oncol Res 2019 Jul 25;27(7):819-826. Epub 2019 Mar 25.

Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang, P.R. China.

Human glioblastoma multiforme (GBM) accounts for the majority of human brain gliomas. Several TMEM proteins, such as TMEM 45A, TMEM 97, and TMEM 140, are implicated in human brain gliomas. However, the roles of TMEM168 in human GBM remain poorly understood. Read More

View Article and Full-Text PDF

Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.

Sci Rep 2019 03 21;9(1):5012. Epub 2019 Mar 21.

Laboratory of Neuroscience, Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, AP, India.

Gliomas are incurable solid tumors with extremely high relapse rate and definite mortality. As gliomas readily acquire resistance to only approved drug, temozolomide (TMZ), there is increasing need to overcome drug resistance by novel therapeutics or by repurposing the existing therapy. In the current study, we investigated antitumor efficacy of roscovitine, a Cdk inhibitor, in combination with TMZ in vitro (U87, U373, LN 18 and C6 cell lines) and in vivo (orthotopic glioma model in Wistar rats) glioma models. Read More

View Article and Full-Text PDF

Accumulation of protoporphyrin IX in medulloblastoma cell lines and sensitivity to subsequent photodynamic treatment.

J Photochem Photobiol B 2018 Dec 7;189:298-305. Epub 2018 Nov 7.

Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Hospital, Moorenstrasse 5, 40225 Düsseldorf, Germany. Electronic address:

Background: Medulloblastoma (MB) is the most common malignant primary brain tumor of childhood. High risk patients still have a poor outcome, and especially young patients suffer from standard therapy induced sequelae. Therefore, other therapeutic options need to be explored. Read More

View Article and Full-Text PDF
December 2018

Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells.

CNS Neurol Disord Drug Targets 2019 ;18(1):29-36

Experimental and Clinical Physiopathology Research Group CTS1039, Department of Health Sciences, Faculty of Health Sciences, University of Jaen, Jaen, Spain.

Background: It has been described that doxazosin, an antihypertensive drug, also promotes glioblastoma cells death by inhibiting cell proliferation, arresting cell cycle and inducing apoptosis. Doxazosin has also demonstrated several modulator effects on renin-angiotensin system (RAS)- regulating aminopeptidase activities, which are highly involved in tumor growth in experimental glioma. Therefore, it remains to elucidate if the anti-tumoral effects of doxazosin could also be mediated by the proteolytic regulatory components of the RAS. Read More

View Article and Full-Text PDF

P2X4R silence suppresses glioma cell growth through BDNF/TrkB/ATF4 signaling pathway.

J Cell Biochem 2019 04 25;120(4):6322-6329. Epub 2018 Oct 25.

Second Ward, Department of Neurosurgery, Huaihe Hospital of Henan University, Kaifeng, China.

Purinergic receptor P2X 4 (P2X4R), a member of purinergic channels family and a subtype of ionotropic adenosine triphosphate receptors, plays a critical role in tumorigenesis. Evidence suggested that P2X4R is expressed in rat C6 glioma model, however, its role and the underlying mechanism of action are still unclear in human glioblastoma multiforme (GBM). In the current study, our aim is to examine the function and the molecular basis of P2X4R in GBM. Read More

View Article and Full-Text PDF

Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with Tc and Lu as Potential Receptor Radiopharmaceuticals.

Molecules 2018 Oct 5;23(10). Epub 2018 Oct 5.

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Gliomas, particularly WHO grade IV glioblastoma multiforme, are one of the most common and aggressive primary tumors of the central nervous system. The neuropeptide, substance P (SP), is the physiological ligand of the neurokinin-1 (NK-1) receptor that is consistently overexpressed in glioblastoma cells. The aim of this work was to study physico-chemical and biological properties of different SP analogues labeled with technetium-99m and lutetium-177 radionuclides. Read More

View Article and Full-Text PDF
October 2018

Salvianolic acid B renders glioma cells more sensitive to radiation via Fis-1-mediated mitochondrial dysfunction.

Biomed Pharmacother 2018 Nov 29;107:1230-1236. Epub 2018 Aug 29.

Department of Neurosurgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.

Glioma remains the leading cause of brain tumor-related death worldwide, and radiation is a standard adjuvant therapy with proven efficacy. Salvianolic acid B (SalB), a bioactive compound isolated from Radix Salviae, has been shown to exert anti-cancer effects in many cancer cell lines, including glioma. This study aimed to investigate whether SalB could affect response to radiation in human glioma cells. Read More

View Article and Full-Text PDF
November 2018

Knockdown of PEBP4 inhibits human glioma cell growth and invasive potential via ERK1/2 signaling pathway.

Mol Carcinog 2019 01 5;58(1):135-143. Epub 2018 Oct 5.

Department of Neurosurgery, Changzheng Hospital, Second Affiliated Hospital of Second Military Medical University, Shanghai, China.

Phosphatidylethanolamine (PE)-binding protein 4 (PEBP4) is an antiapoptotic protein that is aberrantly expressed in various malignancies. We previously demonstrated that PEBP4 expression is dramatically induced in human gliomas and positively correlated with tumor grade and patient survival. However, the function of PEBP4 in human glioma development and underlying mechanisms remain largely unknown. Read More

View Article and Full-Text PDF
January 2019

Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.

Phytomedicine 2018 Oct 8;49:41-51. Epub 2018 Aug 8.

Graduate Institute of Medical Sciences, College of Medicine, Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan; Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Brain Disease Research Center, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address:

Background: Temozolomide (TMZ) is a first-line chemotherapeutic drug for malignant gliomas. Nonetheless, TMZ-induced side effects and drug resistance remain challenges. Our previous study showed the suppressive effects of honokiol on growth of gliomas. Read More

View Article and Full-Text PDF
October 2018

FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.

J Cell Biochem 2019 01 14;120(1):882-893. Epub 2018 Sep 14.

Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, China.

Mesenchymal subtype of glioblastoma (GBM), identified as one of four clinically relevant molecular subtypes, has worst prognosis because of its close relation with the malignant biological properties induced by glial-mesenchymal transition (GMT). However, the molecular mechanism of GMT and its characterized molecule of GBM have not been studied. Forkhead box protein O1 (FOXO1) is at a convergence point of receptor tyrosine kinase signaling as one of the three core pathways implicated in GBM. Read More

View Article and Full-Text PDF
January 2019